| Category | Key points | Evidence | Key source | URL/DOI | Publication date |
|---|---|---|---|---|---|
| Concept | Human **SYP** matches **synaptophysin** (UniProt P08247), also called major synaptic vesicle protein **p38**. It is an abundant synaptic vesicle membrane glycoprotein of ~38 kDa with **four transmembrane segments** and cytosolic N- and C-termini, consistent with the synaptophysin/MARVEL family assignment. | Structural/topology and naming evidence (pqac-00000007, pqac-00000008) | Yuan 2024, *Future Sci OA*; Valtorta 2004, *BioEssays* | https://doi.org/10.1080/20565623.2024.2410146; https://doi.org/10.1002/bies.20012 | Oct 2024; Apr 2004 |
| Localization | SYP localizes predominantly to the **synaptic vesicle membrane** in presynaptic terminals and is widely used as a marker of synapse density, synaptogenesis, and neuronal maturation. | Localization in SVs and marker use (pqac-00000007, pqac-00000008, pqac-00000009) | Yuan 2024, *Future Sci OA*; Valtorta 2004, *BioEssays* | https://doi.org/10.1080/20565623.2024.2410146; https://doi.org/10.1002/bies.20012 | Oct 2024; Apr 2004 |
| Function | Current understanding supports SYP as a **regulator of synaptic vesicle cycling** rather than an essential catalyst of neurotransmitter release. It contributes to vesicle recycling, synaptic plasticity, and maintenance of proper synaptic vesicle protein composition. | Functional synthesis from review and recent biomarker review (pqac-00000001, pqac-00000002, pqac-00000007) | Valtorta 2004, *BioEssays*; Yuan 2024, *Future Sci OA* | https://doi.org/10.1002/bies.20012; https://doi.org/10.1080/20565623.2024.2410146 | Apr 2004; Oct 2024 |
| Interactions | A best-supported interaction is with **synaptobrevin/VAMP2 (sybII)**; SYP also binds **cholesterol**, and reported partners include **dynamin** and **AP-1 γ-adaptin**. The SYP–VAMP2 complex is considered a hallmark of synaptic vesicle maturation and depends on membrane cholesterol. | Interaction evidence (pqac-00000003, pqac-00000005, pqac-00000006) | Gordon 2011, *J Neurosci*; Valtorta 2004, *BioEssays* | https://doi.org/10.1523/JNEUROSCI.3162-11.2011; https://doi.org/10.1002/bies.20012 | Sep 2011; Apr 2004 |
| Mechanism | Mechanistically, SYP helps **retrieve synaptobrevin/VAMP2 during endocytosis** and may bridge vesicle cargo to adaptor machinery through C-terminal tyrosine-based motifs. Reviews also discuss models in which SYP organizes cholesterol-rich microdomains, influences membrane curvature, and may participate in fusion-pore/endocytic coupling, but these broader mechanistic proposals remain less settled than the VAMP2 retrieval role. | Strongest direct evidence is VAMP2 retrieval/endocytosis; additional mechanistic models from review (pqac-00000005, pqac-00000001, pqac-00000004, pqac-00000006) | Gordon 2011, *J Neurosci*; Valtorta 2004, *BioEssays* | https://doi.org/10.1523/JNEUROSCI.3162-11.2011; https://doi.org/10.1002/bies.20012 | Sep 2011; Apr 2004 |
| Quantitative/phenotypic evidence | SYP constitutes roughly **7–10% of total synaptic vesicle protein**. Loss of SYP causes **VAMP dispersion along axons**, trapping at the plasma membrane and impaired vesicle endocytosis; however, conventional knockout mice lack an overt global neurotransmission phenotype, indicating a modulatory rather than absolutely essential role. | Quantitative abundance and KO phenotype summaries (pqac-00000007, pqac-00000004) | Yuan 2024, *Future Sci OA*; Valtorta 2004, *BioEssays* | https://doi.org/10.1080/20565623.2024.2410146; https://doi.org/10.1002/bies.20012 | Oct 2024; Apr 2004 |
| Applications | In practice, SYP is widely implemented as an **immunohistochemical marker** for presynaptic terminals and mature neurons, and is used diagnostically in **neuroendocrine tumors**. Recent review literature notes utility especially in pancreatic neuroendocrine tumor pathology, while emphasizing that diagnostic specificity/accuracy still require validation. | Biomarker and diagnostic application evidence (pqac-00000007, pqac-00000008) | Yuan 2024, *Future Sci OA*; Valtorta 2004, *BioEssays* | https://doi.org/10.1080/20565623.2024.2410146; https://doi.org/10.1002/bies.20012 | Oct 2024; Apr 2004 |
| Disease links | Curated disease-association resources link human **SYP** to **non-syndromic X-linked intellectual disability / neurodevelopmental delay** and broader neurodegenerative or genetic-disorder categories. These associations support clinical relevance but do not by themselves establish mechanism. | Curated association context (pqac-00000000) | Open Targets association context | https://platform.opentargets.org/target/ENSG00000102003 | Accessed via tool context |
| Expert interpretation | Authoritative reviews converge on the view that SYP is a **major structural/regulatory synaptic vesicle protein** whose clearest experimentally supported role is in **vesicle protein trafficking/endocytosis**, especially VAMP2 handling, whereas direct indispensable control of exocytotic release is not supported by knockout studies. | Review synthesis and targeted trafficking study (pqac-00000001, pqac-00000005) | Valtorta 2004, *BioEssays*; Gordon 2011, *J Neurosci* | https://doi.org/10.1002/bies.20012; https://doi.org/10.1523/JNEUROSCI.3162-11.2011 | Apr 2004; Sep 2011 |


*Table: This table summarizes the best-supported functional annotation for human SYP/synaptophysin (UniProt P08247), emphasizing localization, interactions, mechanism, applications, and disease relevance. It uses only the cited evidence contexts from the reviewed literature and Open Targets association data.*